| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | canagliflozin/metformin (Vokanamet®) |
| Formulation | 50 mg/850 mg, 50 mg/1000 mg, 150 mg/850 mg and 150 mg/1000 mg film-coated tablet |
| Reference number | 1618 |
| Indication | Indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients not adequately controlled on their maximally tolerated doses of metformin alone; in patients on their maximally tolerated doses of metformin along with other glucose‑lowering medicinal products including insulin, when these do not provide adequate glycaemic control; or in patients already being treated with the combination of canagliflozin and metformin as separate tablets |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 17/06/2014 |